
    the study was terminated on 24jun15 due to change in strategy of pf-03084014 development.no
    safety/efficacy concerns were behind the reason of trial termination
  
['metastatic cancer pancreas']
['pf-03084014', 'gemcitabine', 'nab-paclitaxel', 'pf-03084014', 'gemcitabine', 'nab-paclitaxel', 'gemcitabine', 'nab-paclitaxel']

        Inclusion Criteria:

          -  Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the
             pancreas.

          -  No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic
             disease. Prior adjuvant therapy with 5-FU or gemcitabine (± gemcitabine post
             radiation) administered as radiosensitizer allowed, provided at least 6 months have
             elapsed between the last dose and study registration

          -  Tumor tissue available (Archival 6 months old or de novo biopsy)

          -  Measurable disease as per RECIST 1.1

          -  Performance Status (ECOG) 0 or 1

        Exclusion Criteria:

          -  Symptomatic brain metastases requiring steroids

          -  Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor

          -  Major surgery within 4 weeks of registration in the current study

          -  Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients

          -  Current or anticipated need for food or drugs that are strong/moderate CYP3A4
             inhibitors or inducers

          -  Diagnosis of any second malignancy within 3 years prior to registration
      